Aileron Therapeutics Inc ALRN.OQ ALRN.O is expected to show no change in quarterly revenue when it reports results on October 28 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for Aileron Therapeutics Inc is for a loss of 41 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aileron Therapeutics Inc is 13.00, above its last closing price of $3.72.
This summary was machine generated October 27 at 14:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments